Evidence map›Paper›PMID 41896932›Full record

ArticleJournal of nanobiotechnology2026

Overcoming lysosomal barrier via V-ATPase: an exosome-based co-delivery platform for combined chemo/RNAi therapy against breast cancer.

Keyao Liu, Tingting Xiong, Xueyuan Wang, Ting Wang, Yudi Wang, Meng Lei, Lihua Shao, Liefeng Zhang, Yongqiang Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Keyao Liu *School of Food and Pharmaceutical Engineering, Normal University, Nanjing, 210023, China.
Tingting Xiong *School of Food and Pharmaceutical Engineering, Normal University, Nanjing, 210023, China.
Xueyuan WangCollege of Life Science, Nanjing Normal University, Nanjing, 210023, China.
Ting WangCollege of Life Science, Nanjing Normal University, Nanjing, 210023, China.
Yudi WangSchool of Food and Pharmaceutical Engineering, Normal University, Nanjing, 210023, China.
Meng LeiCollege of Science, Nanjing Forestry University, Nanjing, 210037, China.
Lihua ShaoDepartment of Colorectal Surgery, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China. digua0024@163.com.
Liefeng ZhangCollege of Life Science, Nanjing Normal University, Nanjing, 210023, China. lfzhang@njnu.edu.cn.
Yongqiang ZhuCollege of Life Science, Nanjing Normal University, Nanjing, 210023, China. zhyqscu@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overcoming the lysosomal entrapment of nanotherapeutics remains a pivotal challenge for efficient drug delivery. Herein, we developed a nano-delivery system, designated as CEL-TPP@siSurvivin/TDNP NPs, consisting of a self-assembled nanocore formed by triphenylphosphine (TPP)-modified celastrol (CEL) and siSurvivin, encapsulated within turmeric-derived nanoparticles (TDNPs), for effective tumor treatment through a combined chemotherapy and gene therapy approach. The TPP modification confers mitochondrial targeting capability to CEL, which acts combinedly with siSurvivin-mediated gene silencing to significantly enhance tumor cell apoptosis. Notably, once the NPs enter cells and become sequestered within lysosomes, they induce the upregulation of the V-ATPase subunits ATP

Indexed as

Breast NeoplasmsExosomesLysosomesVacuolar Proton-Translocating ATPasesAnimalsAntineoplastic AgentsApoptosisCell Line, TumorFemaleHumansMiceMice, Inbred BALB CNanoparticlesOrganophosphorus CompoundsPentacyclic TriterpenesRNA InterferenceAntineoplastic AgentscelastrolOrganophosphorus CompoundsPentacyclic TriterpenestriphenylphosphineVacuolar Proton-Translocating ATPasesCombination therapyLysosomal escapePlant exosomessiSurvivinV-ATPase

Identifiers

PMID41896932
PMCPMC13151111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.